This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Results

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Patients randomised to the treatment arm experienced the following benefits:

  • reduced relapse rates:
    • non-significant at 1 year
    • 18% reduction at 2 years

  • reduced disease burden as assessed by T2-weighted MRI scans

  • a significant delay in six-month confirmed progression of one point on the EDSS:
    • the clinical significance of this difference has been doubted

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.